CDDO is a synthetic oleanane triterpenoid. It is 400,000x more potent than natural product oleanolic acid in inhibiting cellular iNOS production when stimulated by IFN-gamma, TNF-alpha, and IL-1 [1]. The mechanism of action of CDDO remain elusive, despite its broad biological activities, including proliferation inhibition, apoptosis induction[2], and oxidative stress and inflammation suppression.
CDDO-methyl ester,an orally-available form of CDDO, is undergoing clinical development for the treatment of advanced chronic kidney disease (CKD) in type 2 diabetes mellitus patients.
Technical information:
| Chemical Formula: | C31H41NO4 | |
| CAS #: | 218600-44-3 | |
| Molecular Weight: | 491.66 | |
| Purity: | > 98% | |
| Appearance: | Brown | |
| Chemical Name: | 2-cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oic acid | |
| Solubility: | Up to 10 mM in DMSO | |
| Synonyms: | CDDO, RTA-401, RTA401, Bardoxolone |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder or DMSO solution at -20oC desiccated.
Reference:
| 1. | Sporn MB, et al. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod. 2011; 74(3):537-45. Pubmed ID: 21309592 |
| 2. | Suh N, et al. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res. 1999; 59(2):336-41. Pubmed ID: 9927043 |
Other Information:
Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.
